Form 4 for ABUS Arbutus Biopharma Corp
Accepted 2023-02-03 00:00:00 ET · period of report 2023-02-01 · accession 0001447028-23-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-03 | 2023-02-01 | ABUS | Collier William H. | Pres, CEO, Dir | A - Grant | $0.00 | +216.5K | 216.5K | New | $0 |
| D | 2023-02-03 | 2023-02-01 | ABUS | Collier William H. | Pres, CEO, Dir | A - Grant | $0.00 | +866.0K | 866.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-02-01 | A | A | 216,500 | $0.00 | 216,500 | D | — | — | (F1) Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-01 | A | A | 866,000 | $0.00 | 866,000 | D | $2.90 · — to 2033-02-01 | 866,000 Common Shares | (F2) This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |